Clinical Trial: Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07815197) titled 'Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer' on Sept. 02.

Brief Summary: This is a single-arm, Phase 2 clinical trial (PERSEUS TRIAL / LACOG 1924) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (sac-TMT; MK-2870) as a second-line treatment for patients with advanced or metastatic penile cancer. Penile squamous cell carcinoma (PSCC) is a rare and aggressive cancer with limited treatment options once disease progression occurs after initial platinum-based chemotherapy. Sacituzumab tirumotecan is an antibody-drug conjugate (ADC) designed to target TROP-2, a protein frequently expres...